Study evaluates safety of intracameral injection of Fydrane (tropicamide 0.02%, phenylephrine 0.31% and lidocaine 1%) on corneal endothelium, and efficiency in maintaining pupillary dilatation during phacoemulsification surgery.

in this prospective randomized controlled study, 30 eyes of 30 patients undergoing phacoemulsification with intraocular lens (IOL) implantation, were assigned into 2 groups. 15 eyes (Fydrane group) received 0.2ml of Fydrane just after the first incision. While 15 eyes (Reference group) received a topical regimen of one drop of each of cyclopentolate hydrochloride 1% and tropicamide 1 %, every 15 min for 1 hour preoperatively. The main outcome measures were safety on corneal endothelium, by comparing the preoperative and 3 weeks postoperative corneal endothelium cell count in the two groups. Efficacy was also evaluated by measuring pupil size using surgical caliper at certain timings during surgery: before capsulorhexis and before intraocular lens (IOL) implantation, in both groups.

Inclusion Criteria:

• medium density cataract (nuclear II to III)

Exclusion Criteria:

• soft or hard density cataract (nuclear I or IV)
• history of ocular trauma or previous intraocular surgery
• iatrogenic, congenital or traumatic cataract
• associated eye disease e.g. pseudoexofoliation syndrome
• associated pre-existing corneal endothelial disease e.g. Fuchs dystrophy
• associated systemic disease that can affect endothelium,